WO2016004093A3 - Therapeutic compositions including galectin-3 inhibitors and uses thereof - Google Patents

Therapeutic compositions including galectin-3 inhibitors and uses thereof Download PDF

Info

Publication number
WO2016004093A3
WO2016004093A3 PCT/US2015/038645 US2015038645W WO2016004093A3 WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3 US 2015038645 W US2015038645 W US 2015038645W WO 2016004093 A3 WO2016004093 A3 WO 2016004093A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
phe
lys
arg
aromatic
Prior art date
Application number
PCT/US2015/038645
Other languages
French (fr)
Other versions
WO2016004093A2 (en
Inventor
D. Travis Wilson
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of WO2016004093A2 publication Critical patent/WO2016004093A2/en
Publication of WO2016004093A3 publication Critical patent/WO2016004093A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of galectin-3 inhibitors, and/or naturally or artificially occurring derivatives, variants, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to galectin-3 inhibitors and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/038645 2014-07-01 2015-06-30 Therapeutic compositions including galectin-3 inhibitors and uses thereof WO2016004093A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019535P 2014-07-01 2014-07-01
US62/019,535 2014-07-01

Publications (2)

Publication Number Publication Date
WO2016004093A2 WO2016004093A2 (en) 2016-01-07
WO2016004093A3 true WO2016004093A3 (en) 2016-03-03

Family

ID=55020090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/038645 WO2016004093A2 (en) 2014-07-01 2015-06-30 Therapeutic compositions including galectin-3 inhibitors and uses thereof

Country Status (1)

Country Link
WO (1) WO2016004093A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2968443T (en) 2013-03-15 2021-12-10 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3960754A3 (en) 2014-05-16 2022-07-06 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
RU2736637C9 (en) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
JP7498108B2 (en) 2017-08-03 2024-06-11 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー Compounds and their uses for the prevention and treatment of medical disorders - Patents.com
TW201920234A (en) * 2017-09-11 2019-06-01 美商領導醫療有限公司 Opioid agonist peptides and uses thereof
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN112672765A (en) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 Conjugates
WO2020096002A1 (en) * 2018-11-08 2020-05-14 国立大学法人香川大学 Brown/beige adipocyte activating agent containing d-allulose as active ingredient
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021064729A1 (en) * 2019-10-02 2021-04-08 Patchor Ltd. Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
CN112745372B (en) * 2019-10-31 2022-07-12 深圳先进技术研究院 Functional saccharide molecule based on TDG molecular skeleton and preparation method thereof
KR20220129030A (en) * 2020-01-13 2022-09-22 트루바인딩 아이엔씨. Anti-Gal3 Antibodies and Methods of Use
CN115279782A (en) 2020-01-15 2022-11-01 詹森生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4132537A4 (en) * 2020-04-07 2024-05-15 G3P, Inc. Methods and compositions for preventing and treating retinal nerve damage
US20230279052A1 (en) * 2020-06-22 2023-09-07 Stealth Biotherapeutics Inc. Prodrugs of mitochondria-targeting oligopeptides
WO2021262708A1 (en) * 2020-06-22 2021-12-30 Stealth Biotherapeutics Corp. Prodrugs of mitochodria-targeting oligopeptides
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
WO2023023256A1 (en) * 2021-08-18 2023-02-23 Oculogenex Inc. Aav-mediated gene transfer for retinopathy
AU2022388722A1 (en) * 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20070134279A1 (en) * 2005-12-09 2007-06-14 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
US20100311664A1 (en) * 2004-01-23 2010-12-09 Szeto Hazel H Methods for reducing oxidative damage
US20130244957A1 (en) * 2003-02-04 2013-09-19 Hazel H. Szeto Methods for preventing or treating mitochondrial permeability transition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US20130244957A1 (en) * 2003-02-04 2013-09-19 Hazel H. Szeto Methods for preventing or treating mitochondrial permeability transition
WO2005001023A2 (en) * 2003-05-01 2005-01-06 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20100311664A1 (en) * 2004-01-23 2010-12-09 Szeto Hazel H Methods for reducing oxidative damage
US20070134279A1 (en) * 2005-12-09 2007-06-14 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
WO2016004093A2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
PH12016501750A1 (en) Human plasma kallikrein inhibitors
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
MX2014002171A (en) Combination treatments for hepatitis c.
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
WO2012030160A3 (en) Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2021010297A (en) Human plasma kallikrein inhibitors.
WO2016168553A8 (en) Deuterated obeticholic acid
MX2022013450A (en) Pharmaceutical formulations.
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15814758

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 15814758

Country of ref document: EP

Kind code of ref document: A2